Piper Sandler Strengthens Healthcare Equity Research Team with the Addition of Biren Amin
Piper Sandler Strengthens Healthcare Equity Research Team with the Addition of Biren Amin
Piper Sandler Companies (NYSE: PIPR), a leading investment bank, is pleased to announce the addition of Biren Amin as a managing director and senior research analyst to the healthcare equity research team. Amin’s coverage will focus on biotechnology companies.
“We are excited to welcome Biren to the equity research team. His well-respected and recognized biotechnology research experience, along with public and private company CFO experience, will expand and strengthen our industry leading platform of biopharma equity research. We look forward to the value Biren will bring to the firm as we can continue providing clients with actionable and insightful research,” said Michael Cox, co-head of global equities at Piper Sandler.
Prior to joining Piper Sandler, Amin served as the chief financial officer and chief strategy officer at Pyramid Biosciences, a private biotechnology company, where he was responsible for investor relations, capital raising and leading business development activities including monitoring key competitors for therapeutics targeting solid tumors. Before Pyramid Biosciences, Amin served as the chief financial officer at Immuneering Corporation, a public clinical-stage oncology company. He previously spent 10 years at Jefferies Financial Group Inc. covering small and mid-cap biotechnology companies focused on oncology, central nervous system disorders, ophthalmology and rare diseases. Prior to Jefferies Financial Group Inc., Amin spent seven years in various equity research roles covering the biotechnology sector. Amin graduated from University of the Sciences with a bachelor’s degree in pharmacy. He received his master’s degree from Long Island University and his Master of Business Administration degree from the Leonard Stern School of New York University.
ABOUT PIPER SANDLER
Piper Sandler Companies (NYSE: PIPR) is a leading investment bank driven to help clients Realize the Power of Partnership®. Securities brokerage and investment banking services are offered in the U.S. through Piper Sandler & Co., member SIPC and NYSE; in the U.K. through Piper Sandler Ltd., authorized and regulated by the U.K. Financial Conduct Authority; and in Hong Kong through Piper Sandler Hong Kong Limited, authorized and regulated by the Securities and Futures Commission. Alternative asset management and fixed income advisory services are offered through separately registered advisory affiliates.
Follow Piper Sandler: LinkedIn | Facebook | X
©2024. Since 1895. Piper Sandler Companies. 800 Nicollet Mall, Minneapolis, Minnesota 55402-7036
Nick Lawler
Tel: 212 891-8954
nick.lawler@psc.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240318523133/en/
-
Is ServiceNow Stock a Buy After Earnings and Its Investor Day?
-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Markets Brief: Is It Really a Surprising Quarter for Earnings?
-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
After Earnings, Is Coke Stock a Buy, a Sell, or Fairly Valued?
-
Disney Earnings: Improved Streaming Results Come at the Expense of Continued Linear Weakness
-
Apple: We Expect New Models and New Chip to Spur Return to iPad Growth
-
Palantir Earnings: AI Platform Drives Strong Start to 2024
-
What I Hope My 14-Year-Old Learned at Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Amazon Stock a Buy, a Sell, or Fairly Valued?
-
The 10 Best Dividend Stocks
-
3 Stocks With High Dividend Yields That Warren Buffett Likes